Cellytics NK with Lens-Free Shadow Imaging enables rapid, accurate, cost-effective real-time assessment of NK cell activity.

Novel image-derived biomarkers (PPD, WSM-SD, CSP) and an Innate Immunity Index (I³) distinguish healthy from immunocompromised patients.

CSP and I³ show superior prognostic power, with CSP reaching diagnostic accuracy marked by an AUC above 0.95.

CSP and I³ outperform conventional hematological markers, including CD107a expression and interferon-γ release, in immune function assessment.

Successful commercialization of Cellytics NK highlights its clinical utility and transformative impact in real-world immune monitoring.